Second Circuit Agrees that Copay Assistance Programs May Violate the Anti-Kickback Statute
FDA Law
AUGUST 4, 2022
That court granted summary judgment to the government on the APA claim and rejected Pfizer’s narrower reading of the AKS, which would require an element of “corrupt” intent to impose AKS liability. Pfizer emphasized to OIG that it would not offer this copay assistance as part of any advertisement or solicitation for tafamidis.
Let's personalize your content